Paraskevi Krashia

Paraskevi Krashia

Auto-generated profile, based on publicly available information

Paraskevi Krashia

Department of Experimental Neurosciences, IRCCS Santa Lucia Foundation, Rome, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
ANAnnalisa Nobili
Annalisa Nobili
ELEmanuele Claudio Latagliata
Emanuele Claudio Latagliata
Maria ViscomiMaria Viscomi
Maria Viscomi
VCVirve Cavallucci
Virve Cavallucci
DCDebora Cutuli
Debora Cutuli
MDMarcello D’amelio
Marcello D’amelio
Alterations of the dopaminergic (DAergic) system are frequently reported in Alzheimer’s disease (AD) patients and are commonly linked to cognitive and non-cognitive symptoms. However, the cause of DAergic system dysfunction in AD remains to be elucidated. We investigated alterations of the midbrain DAergic system in the Tg2576 mouse model of AD, overexpressing a mutated human amyloid precursor protein (APPswe). Here, we found an age-dependent DAergic neuron loss in the ventral tegmental area (VTA) at pre-plaque stages, although substantia nigra pars compacta (SNpc) DAergic neurons were intact. The selective VTA DAergic neuron degeneration results in lower DA outflow in the hippocampus and nucleus accumbens (NAc) shell. The progression of DAergic cell death correlates with impairments in CA1 synaptic plasticity, memory performance and food reward processing. We conclude that in this mouse model of AD, degeneration of VTA DAergic neurons at pre-plaque stages contributes to memory deficits and dysfunction of reward processing.

2 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
PKParaskevi Krashia
Paraskevi Krashia
ACAlberto Cordella
Alberto Cordella
ANAnnalisa Nobili
Annalisa Nobili
LBLivia La Barbera
Livia La Barbera
MFMauro Federici
Mauro Federici
Nicola Biagio MercuriNicola Biagio Mercuri
Nicola Biagio Mercuri
Neuroinflammation is one of the hallmarks of Parkinson’s disease (PD) and may contribute to midbrain dopamine (DA) neuron degeneration. Recent studies link chronic inflammation with failure to resolve early inflammation, a process operated by specialized pro-resolving mediators, including resolvins. However, the effects of stimulating the resolution of inflammation in PD – to modulate disease progression – still remain unexplored. Here we show that rats overexpressing human α-synuclein (Syn) display altered DA neuron properties, reduced striatal DA outflow and motor deficits prior to nigral degeneration. These early alterations are coupled with microglia activation and perturbations of inflammatory and pro-resolving mediators, namely IFN-γ and resolvin D1 (RvD1). Chronic and early RvD1 administration in Syn rats prevents central and peripheral inflammation, as well as neuronal dysfunction and motor deficits. We also show that endogenous RvD1 is decreased in human patients with early-PD. Our results suggest there is an imbalance between neuroinflammatory and pro-resolving processes in PD.

1 July 2021 in Progress in Neurobiology
Verified
Journal Article
Open access
LBLivia La Barbera
Livia La Barbera
FVFrancescangelo Vedele
Francescangelo Vedele
ANAnnalisa Nobili
Annalisa Nobili
PKParaskevi Krashia
Paraskevi Krashia
ESElena Spoleti
Elena Spoleti
MDMarcello D’aMelio
Marcello D’aMelio
What happens precociously to the brain destined to develop Alzheimer's Disease (AD) still remains to be elucidated and this is one reason why effective AD treatments are missing. Recent experimental and clinical studies indicate that the degeneration of the dopaminergic (DA) neurons in the Ventral Tegmental Area (VTA) could be one of the first events occurring in AD. However, the causes of the increased vulnerability of DA neurons in AD are missing. Here, we deeply investigate the physiology of DA neurons in the VTA before, at the onset, and after onset of VTA neurodegeneration. We use the Tg2576 mouse model of AD, overexpressing a mutated form of the human APP, to identify molecular targets that can be manipulated pharmacologically. We show that in Tg2576 mice, DA neurons of the VTA at the onset of degeneration undergo slight but functionally relevant changes in their electrophysiological properties and cell morphology. Importantly, these changes are associated with accumulation of autophagosomes, suggestive of a dysfunctional autophagy, and with enhanced activation of c-Abl, a tyrosine kinase previously implicated in the pathogenesis of neurodegenerative diseases. Chronic treatment of Tg2576 mice with Nilotinib, a validated c-Abl inhibitor, reduces c-Abl phosphorylation, improves autophagy, reduces Aβ levels and - more importantly - prevents degeneration as well as functional and morphological alterations in DA neurons of the VTA. Interestingly, the drug prevents the reduction of DA outflow to the hippocampus and ameliorates hippocampal-related cognitive functions. Our results strive to identify early pathological brain changes in AD, to provide a rational basis for new therapeutic interventions able to slow down the disease progression.

19 August 2014 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
MSM Squillace
M Squillace
LDL Dodero
L Dodero
MFMassimo Federici
Massimo Federici
SMSara Migliarini
Sara Migliarini
Francesco ErricoFrancesco Errico
Francesco Errico
AGA Gozzi
A Gozzi
Autism spectrum disorders (ASD) are neurodevelopmental conditions characterized by pronounced social and communication deficits and stereotyped behaviours. Recent psychosocial and neuroimaging studies have highlighted reward-processing deficits and reduced dopamine (DA) mesolimbic circuit reactivity in ASD patients. However, the neurobiological and molecular determinants of these deficits remain undetermined. Mouse models recapitulating ASD-like phenotypes could help generate hypotheses about the origin and neurophysiological underpinnings of clinically relevant traits. Here we used functional magnetic resonance imaging (fMRI), behavioural and molecular readouts to probe dopamine neurotransmission responsivity in BTBR T+ Itpr3tf/J mice (BTBR), an inbred mouse line widely used to model ASD-like symptoms owing to its robust social and communication deficits, and high level of repetitive stereotyped behaviours. C57BL/6J (B6) mice were used as normosocial reference comparators. DA reuptake inhibition with GBR 12909 produced significant striatal DA release in both strains, but failed to elicit fMRI activation in widespread forebrain areas of BTBR mice, including mesolimbic reward and striatal terminals. In addition, BTBR mice exhibited no appreciable motor responses to GBR 12909. DA D1 receptor-dependent behavioural and signalling responses were found to be unaltered in BTBR mice, whereas dramatic reductions in pre- and postsynaptic DA D2 and adenosine A2A receptor function was observed in these animals. Overall these results document profoundly compromised DA D2-mediated neurotransmission in BTBR mice, a finding that is likely to have a role in the distinctive social and behavioural deficits exhibited by these mice. Our results call for a deeper investigation of the role of dopaminergic dysfunction in mouse lines exhibiting ASD-like phenotypes, and possibly in ASD patient populations.

1 August 2018 in Neurobiology of Disease
Verified
Journal Article
Closed access
ACAlberto Cordella
Alberto Cordella
PKParaskevi Krashia
Paraskevi Krashia
ANAnnalisa Nobili
Annalisa Nobili
APAnnabella Pignataro
Annabella Pignataro
LBLivia La Barbera
Livia La Barbera
MDMarcello D'AMelio
Marcello D'AMelio

17 May 2019 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
PKParaskevi Krashia
Paraskevi Krashia
ANAnnalisa Nobili
Annalisa Nobili
MDMarcello D'AMelio
Marcello D'AMelio
Unifying Hypothesis of Dopamine Neuron Loss in Neurodegenerative Diseases: Focusing on Alzheimer's Disease